title: Red wine extract decreases pro-inflammatory markers, nuclear factor-κB and inducible NOS, in experimental metabolic syndrome.
abstract: We aimed to analyse the effects of alcohol-free Alibernet red wine extract (AWE) on nitric oxide synthase (NOS) activity and pro-inflammatory markers such as nuclear factor-κB (NFκB) and inducible NOS (iNOS) protein expression in experimental metabolic syndrome. Young 6 week-old male Wistar Kyoto (WKY) and obese, spontaneously hypertensive rats (SHR/N-cp) were divided into control groups and groups treated with AWE (24.2 mg per kg per day) for 3 weeks (n = 6 in each group). Total NOS activity and endothelial NOS (eNOS), iNOS and NFκB (p65) protein expressions were determined in the heart left ventricle and aorta by Western blot and immunohistochemical analysis. All parameters investigated significantly increased in the aorta of SHR/N-cp rats. Pro-inflammatory markers such as NFκB and iNOS were increased in the left ventricle as well. AWE treatment did not affect total NOS activity and eNOS expression in the aorta; however, it was able to decrease NFκB and iNOS protein expression in both the left ventricle and aorta. In conclusion, in the cardiovascular system, Alibernet red wine extract decreased NFκB and iNOS protein expressions elevated as a consequence of developed metabolic syndrome. This effect may represent one of the protective, anti-inflammatory properties of Alibernet red wine polyphenols on cardiovascular risk factors related to metabolic syndrome.
authors: Institute of Normal and Pathological Physiology and Centre of Excellence for Regulatory Role of Nitric Oxide in Civilization Diseases, Slovak Academy of Sciences, Bratislava, Slovak Republic. olga.pechanova@savba.sk.
authors: Pavol
authors: P
authors: Janega
authors: Jana
authors: J
authors: Klimentová
authors: Andrej
authors: A
authors: Barta
authors: Mária
authors: M
authors: Kovácsová
authors: Stanislava
authors: S
authors: Vranková
authors: Martina
authors: M
authors: Cebová
authors: Zuzana
authors: Z
authors: Čierna
authors: Zuzana
authors: Z
authors: Matúsková
authors: Vladimir
authors: V
authors: Jakovljevic
authors: Olga
authors: O
authors: Pechánová
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000032:analysis; D015536:Down-Regulation; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology*; D016328:NF-kappa B / Q000235:genetics* / Q000276:immunology; D052247:Nitric Oxide Synthase Type II / Q000235:genetics* / Q000276:immunology; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000276:immunology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017208:Rats, Wistar; D014920:Wine / Q000032:analysis*
chemical_list: D000893:Anti-Inflammatory Agents; D016328:NF-kappa B; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III